Download PDFPDF

Original research
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Colchicine- A dying hope?
    • Haris Iftikhar, Resident physician Emergency Medicine Hamad Medical Corporation

    Dear Editor

    The small randomized clinical trial by Lopes MI et al. has shown a meaningful benefit of colchicine in COVID- 19 patients. However, there are ambiguities in the written study design including the techniques opted for allocation concealment, blinding, and sample size calculations with six primary endpoints. Investigators were not able to analyze four major endpoints including mortality rate, causes of mortality, admission to ICU, and length of stay in ICU [1]. These results became hard to compare with other major studies such as preliminary findings of the RECOVERY trial where investigators have closed the recruitment of colchicine arm. There was no convincing evidence of mortality benefit in the colchicine group. Final results will show more data on secondary outcomes such as length of hospital stay and need for invasive mechanical ventilation [2].
    This may not be the end of the road for colchicine as 26 study groups have been registered with to prove the beneficial effects of colchicine in COVID patients. At least four of these studies have already been completed. Preprint data from the COLCORONA trial shows a controversial conclusion of reduction in composite rate of death or hospitalization with colchicine in PCR confirmed non hospitalized patients [3]. Another small size COLORIT trial by Mareev V.Yu. et al. showed the median SHOCS score decreased from 8 to 2, i.e., from a moderate to a mild degree in the colchicine group. The...

    Show More
    Conflict of Interest:
    None declared.